Kalli C. Catcott - Concepedia

Author

Kalli C. Catcott

Mersana Therapeutics (United States)ORCID

Also Known As

Kalli C Catcott, Kalli C. Catcott, Kalli Catcott, Kalli Corinne Catcott

116

Publications

375

Citations

H-Index

Concepts

All Affiliations

Mersana Therapeutics (United States)The Ohio State University

About

Kalli C. Catcott is an author at Mersana Therapeutics (United States) specializing in immunotherapy, medicine, and radiation oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	6	6	138
2	Engineering	1	1	33
3	Natural Sciences	1	1	16
4	Allergy	1	1	25
5	Biochemistry	1	1	16

Kalli C. Catcott

Publications

343

Citations

H-Index

Page 1

	Year	Citations
Tumor cell-directed STING agonist antibody-drug conjugates induce type III interferons and anti-tumor innate immune responses Naniye Malli Cetinbas, Travis Monnell, Jahna Soomer-James, Nature Communications	2024	55
Discovery and Optimization of HKT288, a Cadherin-6–Targeting ADC for the Treatment of Ovarian and Renal Cancers Carl Uli Bialucha, Scott D. Collins, Xiao Li, Cancer Discovery	2017	52
Discovery and Optimization of a STING Agonist Platform for Application in Antibody Drug Conjugates Jeremy R. Duvall, Joshua D. Thomas, Raghida A. Bukhalid, Journal of Medicinal Chemistry	2023	44
Discovery and Preclinical Characterization of XMT-1660, an Optimized B7-H4-Targeted Antibody–Drug Conjugate for the Treatment of Cancer Dorin Toader, Shawn P. Fessler, Scott D. Collins, Molecular Cancer Therapeutics EngineeringImmunologyImmunotherapeuticsImmunotherapyTumor Biology	2023	33
Abstract 6706: Systemic administration of STING agonist antibody-drug conjugates elicit potent anti-tumor immune responses with minimal induction of circulating cytokines Raghida A. Bukhalid, Jeremy R. Duvall, Naniye Mallı Cetinbas, Cancer Research Minimal InductionImmunologyImmunologic MechanismBiological TherapyInnate Immunity	2020	25
Abstract 3503: XMT-2056, a HER2-targeted Immunosynthen STING-agonist antibody-drug conjugate, binds a novel epitope of HER2 and shows increased anti-tumor activity in combination with trastuzumab and pertuzumab Jeremy R. Duvall, Raghida A. Bukhalid, Naniye Mallı Cetinbas, Cancer Research ImmunologyImmunoeditingNovel EpitopeImmunotherapeuticsSting Agonist	2022	24
Abstract 1738: XMT-2056, a well-tolerated, Immunosynthen-based STING-agonist antibody-drug conjugate which induces anti-tumor immune activity Jeremy R. Duvall, Raghida A. Bukhalid, Naniye Mallı Cetinbas, Cancer Research NanotherapeuticsAbstract 1738ImmunologyImmunoeditingSting Pathway	2021	23
Microscale screening of antibody libraries as maytansinoid antibody-drug conjugates Kalli C. Catcott, Molly A. McShea, Carl Uli Bialucha, mAbs BioanalysisImmunologyMaytansinoid AdcsAntibody ScreeningImmunochemistry	2016	22
XMT-2056, a HER2-Directed STING Agonist Antibody–Drug Conjugate, Induces Innate Antitumor Immune Responses by Acting on Cancer Cells and Tumor-Resident Immune Cells Raghida A. Bukhalid, Jeremy R. Duvall, Kelly L. Lancaster, Clinical Cancer Research	2025	20
Identifying Unknown Enzyme–Substrate Pairs from the Cellular Milieu with Native Mass Spectrometry Kalli C. Catcott, Jing Yan, Wanlu Qu, ChemBioChem	2017	18

Page 1